Suchergebnisse - "Buti, Maria"

PubPharm (22)

1

Lead-in period and week 8 as predictive tools for response to boceprevir therapy : a retrospective study of Spanish real clinical practice

enthalten in: Gastroenterologia y hepatologia | 2015

von Crespo, J. | Berenguer, M. | Pérez, F. | +7

2

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2) : a randomised, double-blind, placebo-controlled phase 3 trial

enthalten in: Lancet (London, England) | 2014

von Manns, M. | Marcellin, P. | Poordad, F. | +13

ErratumIn: Lancet. 2016 Apr 30;387(10030):1816. - PMID 27203505

3

PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C

enthalten in: Annals of hepatology | 2014

von Ampuero, J. | Del Campo, J. | Rojas, L. | +12

4

Boceprevir plus peginterferon α-2b/ribavirin in chronic hepatitis C genotype 1 : impact of baseline viral load on sustained virologic response

enthalten in: Journal of clinical gastroenterology | 2014

von Gordon, S. | Reddy, K. | Jacobson, I. | +10

5

Quantification of hepatitis B virus HBsAg : clinical implications

enthalten in: Medicina clinica | 2012

von Buti, M. | Rodríguez Frías, F. | Esteban, R.

6

Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C : meta-analyses of randomized, controlled trials and implications for the future

enthalten in: Hepatology (Baltimore, Md.) | 2011

von Di Martino, V. | Richou, C. | Cervoni, J. | +7

7

1990-2010 : two decades of interferon-based therapy

enthalten in: Clinics in liver disease | 2011

von Buti, M. | Esteban, R.

8

Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response

enthalten in: Hepatology (Baltimore, Md.) | 2010

von Buti, M. | Lurie, Y. | Zakharova, N. | +110

CommentIn: Hepatology. 2010 Oct;52(4):1519-20; author reply 1520-1. - PMID 20879035

9

Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV coinfected patients as a function of baseline CD4+ T-cell counts

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2009

von Avidan, N. | Goldstein, D. | Rozenberg, L. | +7

10

Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss : results of a long-term follow-up study in chronic hepatitis B patients

enthalten in: The American journal of gastroenterology | 2009

von Buster, E. | Flink, H. | Simsek, H. | +9